M&A / Deals Eli Lilly maintains M&A streak with $202m Engage Bio buyout Pharmaceutical TechnologyEli Lilly's takeover of Engage Bio marks the seventh acquisition for the big pharma since the start of 2026.Read full story pharminent May 21, 2026 (Last updated: May 21, 2026) Pharmaceutical Technology Eli Lilly’s takeover of Engage Bio marks the seventh acquisition for the big pharma since the start of 2026. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FUJIFILM opens new iPSC facility in Madison, USNext: BioMarin bounces back as Voxzogo performs ‘bigger than expected’ in new indication Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
